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ABSTRACT 
The aim of this study was to investigate the chemical composition and antifungal activity of four commercial 
essential oils from the Burseraceae family - two Boswellia carterii Flueck oils, Canarium luzonicum (Blume) A. 
Gray oil, and Commiphora myrrha (Nees) Engl oil, against most common Candida spp. recovered from the hu-
man oral cavity. The essential oil samples were analyzed by GC-FID and GC/MS. The analysis showed that ma-
jor essential oils’ components were –pinene (23.04 % and 31.84 %), limonene (45.62 %) and curzerene 
(34.65 %), respectively. Minimum inhibitory (MIC) and minimum fungicidal (MFC) concentrations were deter-
mined using a microdilution standardized technique. All tested Candida spp. clinical isolates and ATCC strains 
showed susceptibility to tested essential oils in a dose dependent manner. The strongest antifungal activity was 
shown by essential oil of B. carterii, sample 2; the average MIC values ranged from 1.25 to 1.34 mg/ml, and 
MFC values ranged from 2.50 to 3.75 mg/ml, depending on the fungus. This study supports the possible use of 
essential oils from the Bursecaceae family in reduction and elimination of Candida spp. populations in patients 
with oral cavity fungal infections. 
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INTRODUCTION 
Among the hundreds of microbial species 
from the oral cavity, members of the genus 
Candida are representative of several yeast 
species considered to be commensal oral mi-
crobiota. Among them, Candida albicans is 
the most commonly isolated from the human 
oral cavity (Back-Brito et al., 2009), while 
the non-albicans species, such as C. glabra-
ta, C. krusei, C. tropicalis and C. dublinien-
sis are generally less frequent, although there 
are indications that the incidence of non-
albicans species recovered from cases of oral 
candidosis is increasing (Samaranayake, 
1991; Scully et al., 1994). 
Under certain circumstances Candida 
spp. commensals become pathogens and 
cause mucous membrane infections ranging 
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from pseudomembranous candidodis and 
denture-induced stomatitis (Lam et al., 2012; 
Gonsalves et al., 2007; Da Costa et al., 2006; 
Ben-Aryeh et al., 1980), to life-threatening 
systemic diseases (Samaranayake and Yaa-
cob, 1990), particularly in immunocompro-
mised patients with AIDS, cancer and diabe-
tes mellitus (Seneviratne et al., 2008; Ed-
mond et al., 1999). 
Oral candidosis is an opportunistic infec-
tion usually accompanied by various symp-
toms including burning, painful sensation, 
change of taste and swallowing difficulty, 
but it can be also asymptomatic. It could be 
treated with various synthetic antifungal 
agents, though they possess some disad-
vantages such as high toxicity to the host tis-
sues, emergence of drug-resistant species, 
and high cost (Runyoro et al., 2006). There 
is a number of case reports describing the 
colonization and infection of immunocom-
promised patients or denture wearers sub-
jected to long-term regimens of oral antifun-
gal agents, from which drug less-responsive 
or resistant (Sheehan et al., 1999; Wingard et 
al., 1991; Wingard, 1994 and 1995; Webb et 
al., 1998; Sanglard and Odds, 2002; Sullivan 
et al., 2004), and even cross-resistant Can-
dida spp. (Cross et al., 2000; Magill et al., 
2006) have been recovered. In addition, re-
currences of the oral candidosis, which are 
commonly observed in these patients, make 
the problem even greater (Taplin, 1976). 
Limitations of synthetic antifungal drugs 
have encouraged development of new classes 
of antifungal medications based on potent 
bioactive molecules of natural origin with 
high therapeutic efficiency, low toxicity, 
wide spectrum of activity and eco-friendly 
nature (Saini et al., 2008; Rajeshkumar and 
Sundararaman, 2012). Since plant-derived 
essential oils have a long tradition of use and 
cover a broad spectrum of biological activi-
ties, in various studies their efficacy has been 
tested over a wide range of oral bacteria and 
fungi (Hammer et al., 1999; Carvalhinho et 
al., 2012). Their natural origin, low cytotoxi-
ty and biodegradability made them potential 
ingredients in novel antifungal medications 
intended for use in oral hygiene mainte-
nance, and prevention and management of 
oral infections.  
In addition, mindful of increased re-
sistance of Candida spp. to synthetic anti-
fungal drugs (Pina-Vaz et al., 2004; Zomoro-
dian et al., 2011), testing the susceptibilities 
of clinical isolates to natural products such 
as essential oils, has contributed to develop-
ment of novel antifungal treatments intended 
for use at target sites. Our approach also 
supports the idea that apart from classical 
antifungal treatments, combination therapy 
and preventive therapy represent emerging 
strategies for treating invasive fungal infec-
tions (Rüping et al., 2008). 
The aim of this study was to investigate 
the chemical composition and antifungal ac-
tivity of four commercial essential oils from 
the Burseraceae family against the most 
common Candida spp. recovered from the 
human oral cavity. 
 
MATERIAL AND METHODS 
Essential oils 
Four commercial essential oils belonging 
to the Burseraceae family were used in this 
experiment: 1) Boswellia carterii Flueck., 
sample 1 (EOBC1), purchased from an herb-
al pharmacy in Rotterdam, Holland; 2) Bos-
wellia carterii Flueck., sample 2 (EOBC2), 
purchased from Sensient Essential Oils 
Germany GmbH, Bremen, Germany; 3) Ca-
narium luzonicum (Blume) A. Gray, (EOCL) 
also purchased from Sensient Essential Oils 
Germany GmbH; and 4) Commiphora 
myrrha (Nees) Engl. (EOCM), also pur-
chased from Sensient Essential Oils Germa-
ny GmbH. 
 
Essential oil analyses procedure 
The essential oil analyses procedure for 
Gas Chromatography coupled with a Flame-
Ionization Detector and Gas Chromato-
graphy/Mass Spectrometry analyses meets 
standards ISO 7609:1985, ISO 11024-1:1998, 
and 11024-2:1998, and they have been previ-
ously reported by Nikolić et al. (2013). 
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GC-FID analysis was carried out using a 
GC Agilent Technologies 7890A apparatus, 
equipped with the split-splitless injector and 
automatic liquid sampler (ALS), attached to 
HP-5 column (30 m x 0.32 mm, film thick-
ness 0.25 µm) and fitted with a flame-
ionization detector (FID). Operating condi-
tions were: H2 was the carrier gas (1 ml/min/ 
210 °C); injector and detector T were 250 °C 
and 280 °C, respectively, while the column T 
was linearly programmed 40-260 °C at 
4 °C/min. Samples of essential oils were first 
dissolved in ethanol (approx. 1 %) and then 
injected by ALS (1 µl, split-mode). Presence 
of the oils’ compounds were calculated from 
the peak areas attained in corresponding ar-
ea-percent reports (results of the standard 
processing of chromatograms), without cor-
rection factors. 
The GC/MS was carried out on an HP 
G1800C Series II GCD analytical system 
equipped with a column HP-5MS (30 m x 
0.25 mm, film thickness 0.25 µm). He was 
the carrier gas (1 ml/min). Other chromato-
graphic conditions were identical to those for 
GC-FID. The transfer line was heated at 
260 °C, while the mass spectra were record-
ed in EI mode (70 eV), ranging from 40 to 
450 m/z. Essential oil samples were dis-
solved in ethanol (approx. 1 %) and then in-
jected by ALS (0.2 µl, split mode). 
Identification of the oils’ compounds was 
found on matching of their mass spectra 
peaks with those from libraries of the Wiley 
275 and NIST/NBS. The experimental Ko-
vats’ retention indices (RI values) were ob-
tained by the use of calibrated Automated 
Mass Spectral Deconvolution and Identifica-
tion System software (AMDIS ver. 2.1, 
1997), and compared to those from corre-
sponding literature (Adams, 2007), as an ad-
ditional tool to the MS findings. 
 
Microorganisms 
Clinical isolates of Candida spp. (58) and 
reference strains, Candida albicans ATCC 
10231 and Candida tropicalis ATCC 750 
(from Laboratory for Mycology, Institute for 
Biological Research “S. Stanković”, Univer-
sity of Belgrade, Serbia), were used in this 
study. The clinical isolates were collected by 
rubbing sterile cotton swabs over the oral 
mucosa of randomly chosen patients at the 
Faculty of Dental Medicine, University of 
Belgrade, Serbia.  For collecting clinical iso-
lates, used swabs were transferred to SD 
broth medium which were then thoroughly 
mixed using a vortex mixer; 50 μl of suspen-
sions were subsequently inoculated on vari-
ous selective and non-selective media and 
incubated microaerobically for 48 h at 37 °C. 
The isolates were identified using biochemi-
cal profiles with API 20C (bioMérieux 
France) and Chrom-Agar (Liofilchem sr.l. 
Italy). 
 
Anticandidal activity 
Minimum inhibitory concentrations 
(MIC) and minimum fungicidal concentra-
tions (MFC) were established by the use of 
microdilution standardized technique, EU-
CAST (2002) with modification. In brief, 
with the use of sterile saline, fresh overnight 
yeast cultures were adjusted to a concentra-
tion 1.0 x 105 CFU/per well. The microplates 
were left at 37 °C for 24 h. Following the 
addition of 40 μl P-Iodonitrotetrazolium vio-
let (INT) 0.2 mg/ml (Sigma I8377) and 
30 min of incubation at 37 °C, the MIC of 
samples were determined.  
The MIC values were considered as the 
lowest concentrations without microscopi-
cally observed growth. Following the serial 
sub-cultivations of 10 µl into microtitre 
plates containing 100 µl of broth/well, as 
well as subsequent 24 h incubation at 37 °C, 
the lowest concentrations with no visible 
growth were defined as the MFC values, in-
dicating 99.5 % killing of the original inocu-
lum. 
A mouth rinse with active ingredient 
chlorhexidine 0.05 % (Curasept ADS 205, 
Curaden International AG, Kriens, Swiss) 
was used as a positive control. It is recom-
mended for prophylactic use in order to 
maintain good oral hygiene in seriously dis-
eased patients (Langslet et al., 1974). 
 
EXCLI Journal 2016;15:280-289 – ISSN 1611-2156 
Received: October 02, 2014, accepted: December 13, 2014, published: April 19, 2016 
 
 
 
283 
RESULTS 
Essential oil composition 
The results of GC/MS analysis of com-
mercial essential oils’ samples are presented 
in Table 1. 
 
 
 
 
Table 1: Chemical composition of four commercial oils from the Burseraceae family used in experi-
ment (Presented components contribute to corresponding oils with  0.5 %). 
 
 Constituents RI Contribution to the oil (% m/m) 
B. carterii 
sample 2 
C. luzonicum
 
C. myrrha 
 
B. carterii
sample 1 
1 α-thujene 919 1.8 *  12.0 
2 α-pinene 925 23.0   31.8 
3 sabinene 964 3.1 4.5  5.4 
4 β-pinene 966 *   3.3 
5 myrcene 984 3.2 *  4.1 
6 α-phellandrene 996 * 6.0  1.1 
7 p-cymene 1017 3.8 3.0  6.0 
8 limonene 1021 10.9 45.6  17.9 
9 1,8-cineole 1023  1.1   
10 γ-terpinene  1052  0.5   
11 cis-sabinene hydrate 1061  0.8   
12 terpinen-4-ol 1169 * 0.7  0.8 
13 α-terpineol 1183  4.4   
14 δ-elemene 1328   0.9  
15 α-copaene 1365 3.6   1.2 
16 β-elemene 1382 2.8 * 4.3 1.1 
17 cis-caryophyllene 1407  0.7 0.7  
18 trans-caryophyllene 1408 8.3   5.4 
19 γ-elemene 1423   3.6  
20 α-humulene 1442 3.2 *  1.1 
21 allo-aromadendrene 1449 1.8   * 
22 γ-himachalene 1475 1.8   * 
23 β-selinene 1475   0.7  
24 Curzerene (isofuranogermacrene) 1489   34.7  
25 γ-cadinene 1503 3.5  * 1.2 
26 δ-cadinene 1513 5.8  * 2.1 
27 elemol 1541  21.4   
28 germacrene B 1545   0.9  
29 elemecin 1550  6.2   
30 epicurzerene 1568   0.7  
31 furanoeudesma-1,3-diene 1617   32.8  
32 caryophyllene oxide 1571 11.1   2.1 
33 globulol 1581 2.4   * 
34 lindestrene 1622   10.2  
35 γ-eudesmol 1639  0.9   
36 2-methoxyfurano-diene, isomer I 1631  0.7 1.5  
37 valerianol 1654 4.2   1.2 
38 elemol acetate 1680   1.8  
39 2-methoxyfurano-diene, isomer II 1710     4.8   
 Total  94.4 96.3 97.3 97.9 
RI –Values for retention indices on the HP-5 column; * – Component present in oil, with contribution 
below 0.5 % 
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The main EOBC1 components, (i.e. con-
tributing > 5 %), proved to be –pinene, fol-
lowed by limonene > –thujene > p-cymene 
> sabinene > trans––caryophyllene, all to-
gether comprising 78.5 % of the oil (73.2 % 
monoterpene and 5.4 % of sesquiterpene hy-
drocarbons). The main EOBC2 components 
were –pinene, followed by caryophyllene 
oxide > limonene > trans––caryophyllene > 
–cadinene, which accounted for 59.2 % of 
the oil (33.9 % monoterpene hydrocarbons, 
14.1 % sesquiterpene hydrocarbons and 
11.1 % oxygenated sesquiterpenes). The 
most dominant components of EOCM, typi-
cal for this oil were curzerene, followed by 
furanoeudesma-1,3-diene > lindestrene, 
which together accounted for 77.6 % of the 
entire oil (all oxygenated furano-sesquiter-
penes). The main component of EOCL was 
limonene, followed by elemol > elemecin > 
–phellandrene, together comprising 79.2 % 
of the oil (51.6 % monoterpene hydrocar-
bons, 21.4 % oxygenated sesquiterpenes and 
6.2 % phenylpropane). 
 
Susceptibility of Candida spp. to essential 
oils 
In general, all clinical isolates and ATCC 
strains of Candida spp. proved to be suscep-
tible to tested Burseraceae family essential 
oils in a dose dependent manner. According 
to the lowest calculated average MIC and 
MFC values (2.19 mg/ml and 4.38 mg/ml, 
respectively) it appears that C. krusei, 
ATCC750 and ATCC10231, were generally 
more, and all of them, evenly susceptible to 
application of Burseraceae oils, followed by 
generally more endurable to the oils C. albi-
cans (MIC 2.31 mg/ml and MFC 4.68 mg/ 
ml) and C. glabrata (MIC 2.66 mg/ml and 
MFC 5.31 mg/ml). In comparison to the con-
trol treatment with chlorhexidine mouth 
rinse (MIC 1.02 mg/ml and MFC 2.04 mg/ 
ml, for all tested fungi), susceptibility of 
tested clinical isolates and ATTC strains to 
Burseraceae oils was generally lower.  
Similar trends of susceptibility of all 
tested fungi were observed between the oils, 
although specific oil efficacy varied depend-
ing on the tested fungus. Based on calculated 
average MIC and MFC values, the most effi-
cient essential oil proved to be EOBC2 (MIC 
1.39/MFC 2.79 mg/ml). The least susceptible 
species on application of EOBC2 was a clini-
cal isolate of C. glabrata (average MIC 
1.88/MFC 3.75 mg/ml), followed by a C. 
albicans isolate (average MIC 1.34/MFC 
2.68 mg/ml). The remaining three fungi, C. 
krusei, ATCC750 and ATCC10231, again 
expressed the same susceptibility trend, also 
proved by their equally expressed average 
MIC and MFC values (1.25 and 2.50 mg/ml, 
respectively), which were very close to those 
achieved by chlorhexidine (control). Apart 
from the C. glabrata clinical isolates, the av-
erage susceptibility to EOCM which was the 
lowest observed in this trial (MIC 3.75/MFC 
7.5 mg/ml), isolates of C. albicans also 
demonstrated lower susceptibility, not only 
to EOCM (MIC 2.70/MIC 5.32 mg/ml) but 
also to EOBC2 (MIC 2.68/MFC 5.27 mg/ 
ml). However, the average susceptibilities of 
C. krusei, ATCC750 and ATCC10231 to 
EOCM, EOCLand EOBC1, as well of C. al-
bicans to EOCL and C. glabrata to EOCL 
and EOCM, were all identical (MIC 
2.5/MFC 5.0 mg/ml) (Table 2). 
 
Antifungal efficacy of essential oils 
Among all tested essential oils, generally 
EOBC2 proved to be the most efficacious 
against all fungi at the lowest concentration 
applied; 2.5 mg/ml of this oil successfully 
killed 100 % of C. krusei (1 of 1 isolate), 
ATCC 750 (1 of 1 strain) and ATCC 10231 
(1 of 1 strain), as well as 92.7 % of C. albi-
cans (51 of 55 isolates), and 50 % of C. gla-
brata (1 of 2 isolates). 
Similar trends in activity against C. 
krusei, ATCC 750 and ATCC 10231, were 
observed with EOCM, EOCL and EOBC1, 
but the concentrations required to achieve 
the same effect (100 % kill) was two-times 
greater (5 mg/ml). In addition, a concentra-
tion of 5 mg/ml in the case of EOCL and 
EOBC1 also achieved 100 % killing of C. 
glabrata isolates, but was not as efficacious 
in case of EOCM (50 % kill).  
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Table 2: Anti-candidal activity of four essential oils from the Burseraceae family (mg/ml) 
 Fungal 
strain 
Essential oils of Burseraceae family Control 
No Candida 
spp.* 
B. carterii 
sample 2 
C. myrrha C. luzonicum B. carterii 
sample 1 
Chlorhexidine 
0.05 % 
MIC MFC MIC MFC MIC MFC MIC MFC  MIC MFC 
1 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
2 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
3 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
4 C.a. 1.25 2.5 5 10 2.5 10 2.5 5 1 2 
5 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
6 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
7 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 1.5 
8 C.a. 1.25 2.5 5 10 2.5 5 5 5 1 2 
9 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
10 C.a. 1.25 2.5 5 5 25 10 2.5 5 1 2 
11 C.a. 2.5 5 2.5 5 25 50 2.5 5 1 2 
12 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
13 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1.25 2.5 
14 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
15 C.a. 2.5 5 2.5 5 2.5 5 2.5 5 1 2 
16 C.a. 1.25 2.5 2.5 5 2.5 5 5 10 1 2 
17 C.a. 1.25 2.5 2.5 5 2.5 5 5 10 1 2 
18 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1.25 2.5 
19 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
20 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
21 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
22 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
23 C.a. 1.25 2.5 2.5 5 2.5 5 25 5 1 2 
24 C.a. 1.25 2.5 2.5 5 2.5 5 25 5 1 2 
25 C.a. 1.25 2.5 2.5 5 2.5 5 25 5 1 2 
26 C.a. 1.25 2.5 2.5 5 2.5 10 25 5 1.25 2.5 
27 C.a. 1.25 2.5 2.5 5 2.5 5 25 5 1 2 
28 C.a. 1.25 2.5 2.5 5 2.5 5 25 5 1 2 
29 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
30 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
31 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
32 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
33 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
34 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
35 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
36 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
37 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
38 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
39 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
40 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
41 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
42 C.a. 1.25 2.5 1.25 2.5 2.5 5 2.5 5 1 2 
43 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
44 C.a. 2.5 5 5 10 2.5 10 2.5 5 1 2 
45 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1.25 2.5 
46 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
47 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
48 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
49 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
50 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
51 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
52 C.a. 2.5 5 5 10 2.5 10 5 10 1.25 2.5 
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Table 2 (cont.): Anti-candidal activity of four essential oils from the Burseraceae family (mg/ml) 
 Fungal 
strain 
Essential oils of Burseraceae family Control 
No Candida 
spp.* 
B. carterii 
sample 2 
C. myrrha C. luzonicum B. carterii 
sample 1 
Chlorhexidine 
0.05 % 
MIC MFC MIC MFC MIC MFC MIC MFC  MIC MFC 
53 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
54 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
55 C.a. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
56 C. k. 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
57 C. g. 2.5 5 2.5 5 2.5 5 2.5 5 1 2 
58 C. g. 1.25 2.5 5 10 2.5 5 25 5 1 2 
59 ATCC 10231 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
60 ATCC 750 1.25 2.5 2.5 5 2.5 5 2.5 5 1 2 
* C. a. – C. albicans clinical isolates; C. k. – C. krusei clinical isolate; C. g. – C. glabrata clinical iso-
lates; ATCC 10231 – C. albicans; ATCC 750 – C. tropicalis. MIC – Minimum inhibitory concentration; 
MFC - Minimum fungicidal concentration 
 
 
 
Anti-candidal activity of the same essen-
tial oils against two Boswellia spp., was pre-
viously tested and confirmed (Abdoul-latif et 
al., 2012), as well as a weak anti-candidal 
efficacy of EOCM (Carvalhinho et al., 
2012), in comparison to EOBC, although 
those oils, as well as many other oils and 
their major components were tested only 
against the ATCC 10231 strain (Hammer et 
al., 1999; Tampieri et al., 2005). Although 
this group did not describe the efficacy of 
oils against Candida spp. clinical isolates, 
their data were in accordance with our results 
with regard to the same ATCC strain. On the 
other hand, because of the small number of 
clinical isolates of C. krusei (1) and C. gla-
brata (2) recovered from human oral cavity, 
we are not in position to draw any serious 
conclusions on the efficacy of our essential 
oils, so our findings regarding C. krusei and 
C. glabrata isolates may serve only as a ref-
erence. In addition, our results also confirm 
that C. albicans was the most common oral 
cavity clinical isolate, while the isolates from 
C. glabrata and C. krusei were recovered not 
so frequently but consistently. 
 
DISCUSSION 
The main components of EOBC1 and 
EOBC2 were, typically dominant in mono-
terpenes (Abdoul-latif et al., 2012). Howev-
er, the two oils differed between themselves 
in their individual components percent con-
tribution (Chiavari et al., 1991; Abdulwahab 
et al., 1987). Our EOCM differed from the 
literature in abundance of curzerene (Chiava-
ri et al., 1991), which was greater than the 
previously reported high percentage of 
furanoeudesma-1,3-diene (Baser et al., 
2003), although they were both present in 
similar and quite high percentages (34.65 
and 32.77 %, respectively), as confirmed in 
other articles (Hanuš  et al., 2008; Baser et 
al., 2003). 
To the best of our knowledge, this study 
is the first to emphasize the susceptibility of 
several oral cavity clinical isolates and 
ATCC strains of Candida spp. to these four 
essential oils from the Burseraceae family.  
As out of all tested Candida spp. clinical 
isolates in our experiment, 5 to 10 % re-
sponded differently to applied treatment, in-
cluding the control, we assumed that they 
undergone certain modifications, similarly to 
results of Zomorodian et al. (2011) which 
reported 9.2 % of 206 Candida spp. isolates 
tested on diverse antifungal treatments show-
ing minor mutations. This led us to conclu-
sion that we should seriously take in consid-
eration that it may be one of the reasons for 
antifungal treatment failure.  
In addition, the lower susceptibility of 
the clinical isolates of C. albicans in compar-
ison to the ATCC 10231 strain to plant-
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derived essential oils, as shown in our re-
search, is in accordance with findings from 
other studies (Abdoul-latif et al., 2012), em-
phasizing, once again, the strength of C. al-
bicans clinical isolates, also confirmed for 
isolates recovered from the throat and mouth 
(Paniagua et al., 2002; Manfredi et al., 
2006).  
A successful therapy can be defined as “a 
suitable agent prescribed to treat the right 
organism at an appropriate dosage”. Epide-
miological studies by surveillance to deter-
mine the true frequency of antifungal re-
sistance may be the first step to control the 
emergence of antifungal resistance. Rapid 
identification of fungal pathogens and the 
measurement of the MIC of clinical isolates 
in vitro may be helpful. Knowledge gained 
from studying the mechanisms of antifungal 
resistance may provide ideas on how to limit 
the emergence of resistance to those market-
ed antifungal agents and to develop safer and 
better compounds for the next generation of 
antifungal agents (Anibal et al., 2010). 
Therefore, new treatment strategies, espe-
cially natural, are urgently needed. 
 
CONCLUSION 
In this paper, we encourage the develop-
ment of new therapeutic agents against op-
portunistic fungi of the Candida genera, 
which, as do other microorganisms, have the 
ability to acquire resistance to antimicrobi-
als, especially during prolonged treatments 
such as those associated with immunocom-
promised patients.  
Our results conclusively show suscepti-
bility of C. albicans, C. krusei and C. gla-
brata oral cavity clinical isolates and ATCC 
10231 and ATCC 750 strains to all tested 
commercial oils from the Burseraceae fami-
ly. Although less efficacious on a mg/ml ba-
sis in comparison to the mouth rinse with 
chlohexidine 0.05 %, our findings suggest 
that the sample 2 of Boswellia carterii oil 
(EOBC2) could serve as an alternative, either 
alone or in combination with other antifungal 
agents, for preventive and/or therapeutic 
purposes, in patients prone to recurrent oral 
candidiasis. 
In addition, our findings increase the 
knowledge about biological characteristics of 
Candida spp. isolated from the human oral 
cavity and we consider them very important 
with regard to their raising resistance to 
commercial antifungal drugs and consequent 
antifungal treatment failures. Therefore, this 
research should be understood as contrib-
uting to the overall endeavour of discovering 
alternative approaches to current therapeutic 
challenges. 
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